Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Islet Studies

MAPK Kinase Kinase-1 Is Essential for Cytokine-Induced c-Jun NH2-Terminal Kinase and Nuclear Factor-κB Activation in Human Pancreatic Islet Cells

  1. Dariush Mokhtari1,
  2. Jason W. Myers2 and
  3. Nils Welsh1
  1. 1Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden
  2. 2Department of Biochemistry, Stanford University School of Medicine, Stanford, California
  1. Corresponding author: Nils Welsh, nils.welsh{at}mcb.uu.se
Diabetes 2008 Jul; 57(7): 1896-1904. https://doi.org/10.2337/db07-1670
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Article Figures & Tables

Figures

  • FIG. 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 1.

    Cytokine-induced JNK phosphorylation and NF-κB activation is potentiated by MEKK-1 overexpression in βTC-6 cells. A: βTC-6 cells were transfected with GFP, GFP + wild-type MEKK-1, or GFP + kinase inactive mutant (mut) MEKK-1. The GFP-expressing cells were enriched by fluorescence-activated cell sorting. Two days after the transfection and cell sorting procedure, the cells were lysed, and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting with MEKK-1 and ERK antibodies. A representative blot from one out of three experiments is shown. B: βTC-6 cells transiently overexpressing GFP, GFP + wild-type MEKK-1, or GFP + mut MEKK-1 were either left untreated or treated with a mixture of cytokines (50 units/ml IL-1β, 1,000 units/ml IFN-γ, and 1,000 units/ml TNF-α) 2 days after the transfection and cell sorting procedure. After 30 min of cytokine exposure, the cells were lysed and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting with phospho-specific antibodies against JNK, ERK, or p38. Results from immunoblots were quantified by densitometry. Values of phospho-protein bands were related to those of non–phospho-specific protein bands. Data are presented as means ± SE for three individual experiments. *P < 0.05 using one-way ANOVA followed by Student's t test. C: βTC-6 cells transiently overexpressing GFP, GFP + wild-type MEKK-1, or GFP + mut MEKK-1 were either left untreated or treated with a cytokine mixture (50 units/ml IL-1β, 1,000 units/ml IFN-γ, and 1,000 units/ml TNF-α). After 30 min of cytokine exposure, the cells were lysed, and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting with p65 and IκB antibodies (top panels). Results from immunoblots as the one shown in the top panel were quantified by densitometry (bottom panel). Values of IκB bands were related to those of p65 bands. Data are presented as means ± SE for three individual experiments. *P < 0.05 using one-way ANOVA followed by Student's t test.

  • FIG. 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 2.

    Transient overexpression of MEKK-1 augments cytokine-induced cell death in βTC-6 cells. βTC-6 cells transiently overexpressing GFP, GFP + wild-type MEKK-1, or GFP + mut MEKK-1 were either left untreated or treated with a mixture of cytokines (50 units/ml IL-1β, 1,000 units/ml IFN-γ, and 1,000 units/ml TNF-α) for 48 h corresponding to days 3–4 after the transfection and cell sorting procedure. The cells were then analyzed for cell death by fluorescence microscopy. Results from three separate observations are presented as means ± SE. *P < 0.05 and **P < 0.01, respectively, using one-way ANOVA and Student's t test.

  • FIG. 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 3.

    Cytokine treatment induces MEKK-1 T1383 phosphorylation in βTC-6 cells. βTC-6 cells were either left untreated or treated with a mixture of cytokines (50 units/ml IL-1β, 1,000 units/ml IFN-γ, and 1,000 units/ml TNF-α) for 0.5, 1, or 3 h. After cytokine treatment, the cells were lysed and immunoprecipitated (IP) using MEKK-1 antibody or rabbit IgG as control. The immunoprecipitated proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting using T1383 phospho–MEKK-1 and MEKK-1 antibodies (A). Results from immunoblots, as the one shown in the top panel, were quantified by densitometry (B). MEKK-1 phosphorylation was determined by relating P-MEKK-1 bands to those of total MEKK-1. Data are presented as means ± SE for four individual experiments. *P < 0.05 vs. control using Student's t test.

  • FIG. 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 4.

    Effects of MEKK-1 d-siRNA on MEKK-1 levels and JNK, p38, ERK, or MKK4 activation in dispersed human islet cells. A: Dispersed human islet cells were treated with GL-3 or MEKK-1 d-siRNA. Two days after the d-siRNA treatment, the cells were lysed, and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting with MEKK-1 antibodies. A representative blot from one out of two experiments is shown. B: Dispersed human islet cells were transfected with GL3 d-siRNA or MEKK-1 d-siRNA and either left untreated or treated with a mixture of cytokines (50 units/ml IL-1β, 1,000 units/ml IFN-γ, and 1,000 units/ml TNF-α). After the 30-min cytokine exposure, the cells were lysed, and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting with phospho-specific JNK, ERK, and p38 antibodies. The results were quantified by densitometric scanning of three experiments and expressed as means ± SE. C: Dispersed human islet cells were treated with GL-3 or MEKK-1 d-siRNA. Two days after the d-siRNA treatment, the cells were exposed to 50 units/ml IL-1β. After 30 min of IL-1β treatment, the cells were lysed, and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting. MKK4 activation was determined by calculating the ratios between P-MKK4 intensities and ERK intensities. Values are means ± SE for three observations.

  • FIG. 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 5.

    MEKK-1 is required for IκB degradation in human islet cells. Dispersed human islet cells were transfected with GL3 d-siRNA or MEKK-1 d-siRNA. Two days after the d-siRNA treatment, the cells were incubated with 50 units/ml IL-1β for 30 min. The cells were then lysed, and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting with p65 and IκB antibodies (top panel). Results from immunoblots as the one shown in the top panel were quantified by densitometry. Intensities of IκB and p65 bands were used for calculation of IκB over p65 ratios. Data are presented as means ± SE for three individual experiments. *P < 0.05 using one-way ANOVA followed by Student's t test.

  • FIG. 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 6.

    MEKK-1 is required for IL-1β–induced nuclear translocation of NF-κB. βTC-6 cells (A) and human islet cells (B) were treated with GL3 or MEKK-1 d-siRNA. Two days after the d-siRNA treatment, the cells were exposed to 50 units/ml IL-1β for 30 min. Nuclear extracts were prepared and NF-κB activity was determined by EMSA. The last lane contains nuclear extracts from IL-1β–exposed cells and the p65 antibody to induce a supershift. The bottom panels show densitometric scanning results. Results are means ± SE for three separate experiments. *P < 0.05 vs. GL3 + IL-1β using Student's t test.

  • FIG. 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 7.

    MEKK-1 knockdown attenuates IL-1β–induced iNOS induction in βTC-6 cells. βTC-6 cells were treated with GL3 or MEKK-1 d-siRNA. Forty-eight hours after d-siRNA treatment, the cells were either left untreated or treated with 50 units/ml IL-1β overnight. The cells were then lysed, and proteins were separated by SDS gel electrophoresis and analyzed by immunoblotting with iNOS and ERK antibodies. The percentage of iNOS induction was calculated by relating iNOS bands to those of ERK-1. Data are presented as means ± SE for three individual experiments. *P < 0.05 using Student's t test.

  • FIG. 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    FIG. 8.

    MEKK-1 downregulation protects against cytokine-induced βTC-6 and mouse islet cell death. βTC-6 cells (A) and dispersed mouse islet cells (B) that had been transfected with GL3 or MEKK-1 d-siRNA were either left untreated or treated with a mixture of cytokines (50 units/ml IL-1β, 1,000 units/ml IFN-γ, and 1,000 units/ml TNF-α) for 48 h and analyzed for cell death by vital staining with bisbenzimide and propidium iodide followed by fluorescence microscopy. Results from three separate observations are shown in A and are given as means ± SE. *P < 0.05 using Student's paired t test. B: Results from eight separate observations are shown as means ± SE. *P < 0.05 using repeated measurement two-way ANOVA followed by Student's t test.

PreviousNext
Back to top

In this Issue

July 2008, 57(7)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
MAPK Kinase Kinase-1 Is Essential for Cytokine-Induced c-Jun NH2-Terminal Kinase and Nuclear Factor-κB Activation in Human Pancreatic Islet Cells
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
MAPK Kinase Kinase-1 Is Essential for Cytokine-Induced c-Jun NH2-Terminal Kinase and Nuclear Factor-κB Activation in Human Pancreatic Islet Cells
Dariush Mokhtari, Jason W. Myers, Nils Welsh
Diabetes Jul 2008, 57 (7) 1896-1904; DOI: 10.2337/db07-1670

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

MAPK Kinase Kinase-1 Is Essential for Cytokine-Induced c-Jun NH2-Terminal Kinase and Nuclear Factor-κB Activation in Human Pancreatic Islet Cells
Dariush Mokhtari, Jason W. Myers, Nils Welsh
Diabetes Jul 2008, 57 (7) 1896-1904; DOI: 10.2337/db07-1670
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucagon Resistance and Decreased Susceptibility to Diabetes in a Model of Chronic Hyperglucagonemia
  • Acyl-Ghrelin Influences Pancreatic β-Cell Function by Interference with KATP Channels
  • Pancreatic β-Cell–Specific Deletion of VPS41 Causes Diabetes Due to Defects in Insulin Secretion
Show more Islet Studies

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.